Clinical trial · no report yet · Phase 2
KEYNOTE-799
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
- NCT03631784 ↗
- Completed
- Merck Sharp & Dohme LLC
- 17 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 8 | |
| YouTube | 5 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Pembrolizumab 200 mg; Paclitaxel 45 mg/m^2; Carboplatin AUC6; Cisplatin 75 mg/m^2; Pemetrexed 500 mg/m^2; Thoracic Radiation Therapy (TRT); Paclitaxel 200 mg/m^2; Carboplatin AUC2
- Arms
- Cohort A · Experimental
- Cohort B · Experimental
- Enrollment
- 216
- Primary outcomes
- Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis
- Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- Oct 19, 2018
- Primary completion
- Oct 18, 2021
- Results posted
- Yes
- Registry record
- NCT03631784 · updated Mar 25, 2025
Publications
linked from the registry- Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. Online ahead of print. PubMed 34086039